Trial Profile
Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms SHIFT
- Sponsors IRIS; Servier
- 24 Apr 2023 Results of post-hoc analysis assessing the clinical significance of the time durations of heart rate reduction and the significant treatment effect on outcomes among patients with heart failure and reduced ejection fraction, published in the European Journal of Heart Failure.
- 27 Feb 2021 Results of meta-analysis of 6 studies, published in the Clinical Cardiology.
- 18 Nov 2019 Results assessing impact on the outcome adjudication of the Systolic Heart failure treatment, presented at the American Heart Association Scientific Sessions 2019.